First ever malaria vaccine underway

On a major international conference on malaria David Kaslow (PATH Malaria Vaccine Initiative) presented the results of the extensive trials held on 15.000 children in various African trial sites. The vaccine has been developed by GlaxoSmithKline.
The vaccine – called RTS,S – was tested on babies from 6 to 12 weeks and on toddlers aged 5 to 7 months. The older children in particular responded well to the vaccine: after 18 months there were 56% less malaria cases in the group. The smaller babies showed 46% less malaria cases.
From the average incidence of malaria across the 11 sites, combined with the fact that single children are prone to as many as four infections a year, the researchers calculate that the jab has the potential to prevent 941 cases of malaria per 1000 children vaccinated in the older age group, and 444 in the babies.
Meest Gelezen
Wat vindt BBB eigenlijk van hoger onderwijs?
Susanne Täuber: "Wie haar klacht niet laat afzwakken, wordt kapotgemaakt"
Europese Unie: ‘Academische vrijheid in Nederland verslechtert’
'Studentenwelzijn verbeteren zonder wetenschappelijk bewijs kan veel schade toebrengen'
Nederlandse universiteiten dalen op vrijwel alle domeinen in de QS-ranking
